Report cover image

Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry - Implications and Outlook - 2023 Edition

Publisher GlobalData
Published Jun 30, 2023
Length 58 Pages
SKU # GBDT18089836

Description

Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry - Implications and Outlook - 2023 Edition


Summary

This report is the fourth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

This 59-page report gives important, expert insight you won’t find in any other source. 12 tables and 20 figures throughout the report illustrate major points and trends. This report is required reading for -
  • CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
  • Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
  • Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking
Reasons to Buy
  • Overview of M&A in the Pharma CMO Industry
  • Detailed view of CDMO performance by number of deals, based on GlobalData's Deals database
  • Analysis of M&A and private equity investment by target's specific manufacturing services

Table of Contents

58 Pages
About GlobalData
Executive Summary
Players
Technology Briefing
Deal types
Trends
Industry Analysis
Objectives and methodology
Overview of M&A activity 2021-22
Target characteristics
Acquirer characteristics
Geography
Top acquirers
Catalent’s deal activity
Recipharm’s deal activity
Segment close-ups of M&A activity, 2021-22
Deal advisors
Top financial advisors
Top legal advisors
Valuations
Facility acquisitions
What it means
The outlook for M&A
API—biologic targets
API—cell and gene therapy targets
Value Chain
Companies
Appendix
Methodology
Bibliography
Primary research - key opinion leaders
Further reading
About the Authors
Contact Us
List of Tables
Table 1: CMO M&A trends, 2021-22
Table 2: Company acquisitions by target service offering and year, 2018-22
Table 3: Company acquisitions by target service offering and target ownership, 2021-22
Table 4: Company acquisitions by target service offering and deal region, 2021-22
Table 5: Company acquisitions by target service offering and acquirer ownership, 2021-22
Table 6: Services deals with known transaction value and multiples, 2021-22
Table 7: Facility acquisitions by CMOs, 2021-22
Table 8: Acquisitions by PE firms, 2021-22
Table 9: Potential targets: API—biologic (protein & peptide) service providers
Table 10: Potential targets: API—biologic (gene and cell therapy) service providers
Table 11: Company acquisitions and private equity deals, 2021-22
Table 12: Further reading
List of Figures
Figure 1: CMO M&A activity by year, 2018-22
Figure 2: Leading acquirers in the global pharma CMO industry, 2021-22
Figure 3: Top M&A trends in the CMO industry, 2021-22
Figure 4: CMO M&A activity, 2021-22
Figure 5: CMO M&A activity by year, 2018-22
Figure 6: CMO M&A activity percentage change by year, 2018-22
Figure 7: Company acquisitions by target service offering, 2021-22
Figure 8: Company acquisitions by target ownership, 2021-22
Figure 9: Company acquisitions by target ownership and service type, 2021-22
Figure 10: Acquisition targets by sophistication of capabilities, 2021-22
Figure 11: Number of acquisitions 2021-22 by acquirer’s core business
Figure 12: Number of acquisitions by acquirer’s ownership
Figure 13: Number of acquisitions by acquirer’s ownership and target service type
Figure 14: Number of acquisitions by top deal countries, 2021-22
Figure 15: Most active acquirers, 2021-22
Figure 16: Dose forms manufactured by acquired dose manufacturers, 2021-22
Figure 17: Top financial advisors to company acquisitions, 2021-22
Figure 18: Top legal advisors to company acquisitions, 2021-22
Figure 19: Pharma CMO facility acquisitions, 2021-22
Figure 20: The contract manufacturing value chain

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us